Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
Ali Al‐Janabi, Zoe Littlewood, C.E.M. Griffiths, H.J.A. Hunter, Hector Chinoy, Cassie Moriarty, Zenas Z N Yiu, Richard B. Warren
Abstract
There are few data on whether immunomodulator therapy attenuates humoral response to vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some vaccines require two doses for maximum protection, with international variation in dosing schedules. A 3 month interval between doses is being used in the U.K. We evaluated antibody titres to SARS-CoV-2 following initial-dose BNT162b2 (Pfizer/BioNTech) or AZD1222 (AstraZeneca) vaccines in adults with psoriasis and other immune-mediated inflammatory diseases (IMIDs) receiving biologic and/or oral non-biologic immunomodulators.
Topics & Concepts
MedicineImmune systemImmunologyVaccinationAntibodyPsoriasisDosingAntibody responseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)DiseaseInfectious disease (medical specialty)Internal medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses